Dr. Philipp Lehmann

About Dr. Philipp Lehmann

Philipp is Counsel in our M&A practice and part of our Healthcare and Technology sector groups.

Philipp mainly advises on complex operational contracts as well as all questions concerning intellectual property and information technology law in the context of cross-border transactions. The main focus of his work is the structuring of carve-outs and similar transactions. Philipp has specific industry knowledge, in particular in the healthcare, technology and automotive sectors. His particular strength lies in the drafting and negotiation of complex commercial contracts and the structuring of collaborations and joint ventures.

Recent work

• Healthcare
  • Novartis on the separation and spin-off of Sandoz, its generics and biosimilars division ('Spin-off'). As a consequence of the Spin-off, Sandoz has become an independent, publicly traded company on the SIX Swiss Exchange with ADRs traded on the over-the-counter market in the US.
  • Novartis on its collaboration and license agreement with Ionis Pharmaceuticals for the discovery, development and commercialization of a novel medicine for patients with certain cardiovascular diseases
  • Moderna on a strategic collaboration and license of CytomX's Probody technology for use with Moderna's mRNA therapeutics, including a $35 million upfront cash payment and up to $1.2 billion in milestones
  • BioNTech in licensing deals and other collaborations in respect of individualized therapies for treatment of cancer and infectious diseases, including with Pfizer regarding a vaccine program to prevent COVID-19
  • Fresenius on its divestment of IVF services provider Eugin Group to a consortium of global fertility group IVI RMA (a KKR portfolio company) and GED Capital for up to € 500 million including earn-outs
  • SERB Pharmaceuticals on its US partnership with SFJ Pharmaceuticals and the acquisition of exclusive rights in the US to the ticagrelor reversal agent bentracimab 
  • Indivumed GmbH, the industry leader in the provision and analysis of clinical biospecimen material, on the carve-out and subsequent sale of its service division "IndivuServ" to Crown Bioscience, Inc.
  • Grünenthal on a joint venture collaboration with Kyowa Kirin International, the Japan-based global specialty pharmaceutical company, in relation to Kyowa Kirin's established drug portfolio of 13 brands across six therapeutic areas with a focus on pain management
  • Grünenthal on its €500m acquisition of testosterone business ("Nebido") from Bayer
  • Alexion, AstraZeneca Rare Disease on the acquisition of LogicBio Therapeutics, a pioneering genomic medicine company
  • Novartis on its proposed acquisition of GSK's cephalosporin business
  • AstraZeneca on its $39bn acquisition of Alexion Pharmaceuticals
  • Qatar Investment Authority on an investment in the German biotech company CureVac
  • EQT on the acquisition of Schülke & Mayr GmbH, one of the leading suppliers of hygiene and infection prevention solutions for skin and surfaces and wound antiseptics
  • EQT Infrastructure on the acquisition of two major radiology providers in Germany (Meine Radiologie Holding GmbH & Blikk Holding GmbH) with the aim of creating the leading company in this sector in Germany
  • ViGeneron on strategic collaborations with pharma partners, including its collaborations with Biogen and Regeneron
• Technology
  • Umicore on a joint venture with VW to produce battery materials for VW electric vehicles, creating Europe's first all-encompassing supply chain for battery production
  • Bauer Media Group on the merger of part of its Online Comparison Platform (OCP) business with Netrisk Group in a total of six Central and Eastern European (CEE) countries in the form of a joint venture to create one of the largest OCP platforms in Europe
  • Apax Partners and Warpurg Pincus on their €5.1bn acquisition of T-Mobile Netherlands
  • Permira on its €1.9bn strategic investment in Adevinta ASA, the provider of a global classifieds platform
  • The shareholders of Flaschenpost SE on the sale of the business to an entity of Oetker-Group 
  • Hellman & Friedman on its €2.9bn acquisition of the internet platforms AutoScout24, FinanceScout24 und Finanzcheck as well as certain follow-up transactions, inlcuding the on-sale of Finanzcheck to smava
  • Hellman & Friedman on its voluntary public takeover offer for the shares of Zooplus AG
  • Cazoo, the leading UK online car retailer, on its acquisition of Cluno, Germany’s leading consumer car subscription platform
  • UniCredit Bank AG on a high-volume multijurisdictional outsourcing of its payment processing business (ITO and BPO) to equensWorldline  
  • Uber Technologies, Inc. on the sale of its European digital freight business to sennder GmbH
• Other
  • BorgWarner on its voluntary public takeover offer to acquire all outstanding shares of Akasol, a leading manufacturer of battery systems and technologies 
  • Continental on the Spin-Off of its Powertrain Business ("Vitesco Technologies")
  • thyssenkrupp AG on Carve-Out and sale of its plant enineering business in the mining technologies segment 
  • Flint Group, a global supplier to the printing industry, on the Carve-Out and subsequent sale of the XSYS division
  • Porsche SE on its IPO